Decreased glutathione levels and altered antioxidant defense in an animal model of schizophrenia: Long-term effects of perinatal phencyclidine administration

Neuropharmacology

Volumn 58, Issue 4-5, 2010, Pages 739-745

  Radonjić, Nevena V ^a   Knežević, Iva D ^a   Vilimanovich, Urosh ^a   Kravić Stevović, Tamara ^a   Marina, Ljiljana V ^b   Nikolić, Tatjana ^a   Todorović, Veljko ^c   Bumbaširević, Vladimir ^a   Petronijević, Nataša D ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b CLINICAL CENTER OF SERBIA   (Serbia)

^c UNIVERSITY OF DEFENCE   (Serbia)

Author keywords

Antioxidant enzymes; Glutathione; Phencyclidine; Schizophrenia

Indexed keywords

ANTIOXIDANT; CATALASE; COPPER ZINC SUPEROXIDE DISMUTASE; GLUTAMATE CYSTEINE LIGASE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; LIPID PEROXIDE; MANGANESE SUPEROXIDE DISMUTASE; PHENCYCLIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAUDATE NUCLEUS; CONTROLLED STUDY; FEMALE; FRONTAL CORTEX; HIPPOCAMPUS; LONG TERM EXPOSURE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SCHIZOPHRENIA; THALAMUS;

EID: 77649341846     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2009.12.009     Document Type: Article

References (66)

1. Abdalla D.S., Monteiro H.P., Oliveira J.A., Bechara E.J. Activities of superoxide dismutase and glutathione peroxidase in schizophrenic and manic-depressive patients. Clinical Chemistry 1986, 32:805-807.
2. Adams S.M., de Rivero Vaccari J.C., Corriveau R.A. Pronounced cell death in the absence of NMDA receptors in the developing somatosensory thalamus. Journal of Neuroscience 2004, 24:9441-9450.
3. Alelu-Paz R., Gimenez-Amaya J. The mediodorsal thalamic nucleus and schizophrenia. Journal of Psychiatry and Neuroscience 2008, 33:489-498.
4. Baker D.A., Madayag A., Kristiansen L.V., Meador-Woodruff J.H., Haroutunian V., Raju I. Contribution of cystine-glutamate antiporters to the psychotomimetic effects of phencyclidine. Neuropsychopharmacology 2007, 33:1760-1772.
5. Baker D.A., Madayag A., Kristiansen L.V., Meador-Woodruff J.H., Haroutunian V., Raju I. Contribution of cystine-glutamate antiporters to the psychotomimetic effects of phencyclidine. Neuropsychopharmacology 2008, 33:1760-1772.
6. Bannai S. Exchange of cystine and glutamate across plasma membrane of human fibroblasts. Journal of Biological Chemistry 1986, 261:2256-2263.
7. Behrens M.M., Ali S.S., Dao D.N., Lucero J., Shekhtman G., Quick K.L., Dugan L.L. Ketamine-induced loss of phenotype of fast-spiking interneurons is mediated by NADPH-oxidase. Science 2007, 318:1645-1647.
8. Carlberg I., Mannervik B. Glutathione reductase. Methods in Enzymology 1985, 113:484-490.
9. Chipana C., García-Ratés S., Camarasa J., Pubill D., Escubedo E. Different oxidative profile and nicotinic receptor interaction of amphetamine and 3,4-methylenedioxy-methamphetamine. Neurochemistry International 2008, 52:401-410.
10. Choi Y.B., Lipton S.A. Redox modulation of the NMDA receptor. Cellular and Molecular Life Sciences 2000, 57:1535-1541.
11. Cosgrove J., Newell T. Recovery of neuropsychological functions during reduction in use of phencyclidine. Journal of Clinical Psychology 1991, 47:159-169.
12. Danbolt N.C. Glutamate uptake. Progress in Neurobiology 2001, 65:1-105.
13. Do, K.Q., Cabungcal, J.H., Frank, A., Steullet, P., Cuenod, M., 2009. Redox dysregulation, neurodevelopment, and schizophrenia. Current Opinion in Neurobiology, 19, 220-230.
14. Do K.Q., Trabesinger A.H., Kirsten-Krüger M., Lauer C.J., Dydak U., Hell D., Holsboer F., Boesiger P., Cuénod M. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. European Journal of Neuroscience 2000, 12:3721-3728.
15. Ellman G.L. Tissue sulfhydryl groups. Archives of Biochemistry and Biophysics 1959, 82:70-77.
16. Friston K., Frith C. Schizophrenia: a disconnection syndrome?. Clinical Neuroscience 1995, 3:89-97.
17. Golse B., Debray-Ritzen P., Puget K., Michelson A.M. Analysis of platelet superoxide dismutase 1 in the development of childhood psychoses. La Nouvelle presse médicale 1977, 6:2449.
18. Góth L. A simple method for determination of serum catalase activity and revision of reference range. Clinica Chimica Acta 1991, 196:143-151.
19. Günzler W.A., Kremers H., Flohé L. An improved coupled test procedure for glutathione peroxidase (EC 1-11-1-9-) in blood. Zeitschrift für klinische Chemie und klinische Biochemie 1974, 12:444-448.
20. Gysin R., Kraftsik R., Sandell J., Bovet P., Chappuis C.L., Conus P., Deppen P., Preisig M., Ruiz V., Steullet P., Tosic M., Werge T., Cuénod M., Do K.Q. Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:16621-16626.
21. Herken H., Uz E., Ozyurt H., Söĝüt S., Virit O., Akyol O. Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia. Molecular Psychiatry 2001, 6:66-73.
22. Hori H., Ohmori O., Shinkai T., Kojima H., Okano C., Suzuki T., Nakamura J. Manganese superoxide dismutase gene polymorphism and schizophrenia: relation to tardive dyskinesia. Neuropsychopharmacology 2000, 23:170-177.
23. Ikonomidou C., Bosch F., Miksa M., Bittigau P., Vöckler J., Dikranian K., Tenkova T.I., Stefovska V., Turski L., Olney J.W. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science 1999, 283:70-74.
24. James-Walke N.L., Williams H.L., Taylor D.A., McMillen B.A. Periadolescent nicotine exposure produces sensitization to reinforcement by diazepam in the rat. Neurotoxicology and Teratology 2006, 29:31-36.
25. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. American Journal of Psychiatry 1991, 148:1301-1308.
26. Jones D.P. Radical-free biology of oxidative stress. American Journal of Physiology: Cell Physiology 2008, 295:C849-C868.
27. Köhr G., Eckardt S., Lüddens H., Monyer H., Seeburg P.H. NMDA receptor channels: subunit-specific potentiation by reducing agents. Neuron 1994, 12:1031-1040.
28. Lipton S.A. Redox sensitivity of NMDA receptors. Methods in Molecular Biology 1999, 128:121-130.
29. Lipton S.A., Choi Y.-B., Takahashi H., Zhang D., Li W., Godzik A., Bankston L.A. Cysteine regulation of protein function - as exemplified by NMDA-receptor modulation. Trends in Neurosciences 2002, 25:474-480.
30. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the folin phenol reagent. Journal of Biological Chemistry 1951, 193:265-275.
31. Mahadik S.P., Evans D., Lal H. Oxidative stress and role of antioxidant and [omega]-3 essential fatty acid supplementation in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2001, 25:463-493.
32. Mahadik S.P., Mukherjee S., Scheffer R., Correnti E.E., Mahadik J.S. Elevated plasma lipid peroxides at the onset of nonaffective psychosis. Biological Psychiatry 1998, 43:674-679.
33. Marek G.J., Wright R.A., Schoepp D.D., Monn J.A., Aghajanian G.K. Physiological antagonism between 5-hydroxytryptamine2A and group II metabotropic glutamate receptors in prefrontal cortex. Journal of Pharmacology and Experimental Therapeutics 2000, 292:76-87.
34. Matsuzawa D., Obata T., Shirayama Y., Nonaka H., Kanazawa Y., Yoshitome E., Takanashi J., Matsuda T., Shimizu E., Ikehira H., Iyo M., Hashimoto K. Negative correlation between brain glutathione level and negative symptoms in schizophrenia: a 3T 1H-MRS study. PLoS ONE 2008, 3:e1944.
35. Meister A., Anderson M.E. Glutathione. Annual Review of Biochemistry 1983, 52:711-760.
36. Mićić D., Petronijević N. Acetylcholinesterase activity in the mongolian gerbil brain after acute poisoning with aluminum. Journal of Alzheimer's Disease 2000, 2:1-6.
37. Mićić D., Petronijević N., Vučetić S. Superoxide dismutase activity in the Mongolian gerbil brain after acute poisoning with aluminum. Journal of Alzheimer's Disease 2003, 5:49-56.
38. Ozyurt B., Ozyurt H., Akpolat N., Erdogan H., Sarsilmaz M. Oxidative stress in prefrontal cortex of rat exposed to MK-801 and protective effects of CAPE. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2007, 31:832-838.
39. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 2005, Academic Press.
40. Petronijević N.D., Micic D.V., Duricic B., Marinkovic D., Paunovic V.R. Substrate kinetics of erythrocyte membrane Na, K-ATPase and lipid peroxides in schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2003, 27:431-440.
41. Radonjić N.V., Petronijević N.D., Vučković S.M., Prostran M.S., Nešić Z.I., Todorović V.R., Paunović V.R. Baseline temperature in an animal model of schizophrenia: long-term effects of perinatal phencyclidine administration. Physiology & Behavior 2008, 93:437-443.
42. Raffa, M., Mechri, A., Othman, L.B., Fendri, C., Gaha, L., Kerkeni, A., 2009. Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 33, 1178-1183.
43. Reddy R., Keshavan M., Yao J.K. Reduced plasma antioxidants in first-episode patients with schizophrenia. Schizophrenia Research 2003, 62:205-212.
44. Reddy R., Sahebarao M.P., Mukherjee S., Murthy J.N. Enzymes of the antioxidant defense system in chronic schizophrenic patients. Biological Psychiatry 1991, 30:409-412.
45. Reddy R.D., Yao J.K. Free radical pathology in schizophrenia: a review. Prostaglandins, Leukotrienes and Essential Fatty Acids 1996, 55:33-43.
46. Rehncrona S., Smith D.S., Akesson B., Westerberg E., Siesjö B.K. Peroxidative changes in brain cortical fatty acids and phospholipids, as characterized during Fe2+- and ascorbic acid-stimulated lipid peroxidation in vitro. Journal of Neurochemistry 1980, 34:1630-1638.
47. Robinson T., Becker J. Enduring changes in brain and behavior produced by chronic amphetamine administration: a review and evaluation of animal models of amphetamine psychosis. Brain Research 1986, 396:157-198.
48. Scheffer R., Diamond B.I., Correnti E.E., Borison R.L., Mahadik S.P., Mukherjee S. Plasma lipid peroxidation and HVA in first episode psychosis. Biological Psychiatry 1995, 37:681.
49. Seelig G., Meister A. Glutathione biosynthesis; gamma-glutamylcysteine synthetase from rat kidney. Methods in Enzymology 1985, 113:379-390.
50. Shimoda-Matsubayashi S., Matsumine H., Kobayashi T., Nakagawa-Hattori Y., Shimizu Y., Mizuno Y. Structural dimorphism in the mitochondrial targeting sequence in the human manganese superoxide dismutase gene: a predictive evidence for conformational change to influence mitochondrial transport and a study of allelic association in Parkinson's disease. Biochemical and Biophysical Research Communications 1996, 226:561-565.
51. Snyder S. Amphetamine psychosis: a "model" schizophrenia mediated by catecholamines. Am J Psychiatry 1973, 130:61-67.
52. Sun M., Zigman S. An improved spectrophotometric assay for superoxide dismutase based on epinephrine autoxidation. Analytical Biochemistry 1978, 90:81-89.
53. Terpstra M., Henry P., Gruetter P. Measurement of reduced glutathione (GSH) in human brain using LCModel analysis of difference-edited spectra. Magnetic Resonance in Medicine 2003, 50:19-23.
54. Tošić M., Ott J., Barral S., Bovet P., Deppen P., Gheorghita F., Matthey M.-L., Parnas J., Preisig M., Saraga M., Solida A., Timm S., Wang A.G., Werge T., Cuénod M., Quang Do K. Schizophrenia and oxidative stress: glutamate cysteine ligase modifier as a susceptibility gene. The American Journal of Human Genetics 2006, 79:586-592.
55. Tsai G., Coyle J.T. Glutamatergic mechanisms in schizophrenia. Annual Review of Pharmacology and Toxicology 2002, 42:165-179.
56. Tsai G., Goff D.C., Chang R.W., Flood J., Baer L., Coyle J.T. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. American Journal of Psychiatry 1998, 155:1207-1213.
57. Wang C., McInnis J., Ross-Sanchez M., Shinnick-Gallagher P., Wiley J.L., Johnson K.M. Long-term behavioral and neurodegenerative effects of perinatal phencyclidine administration: implications for schizophrenia. Neuroscience 2001, 107:535-550.
58. Wang C., McInnis J., West J.B., Bao J., Anastasio N., Guidry J.A., Ye Y., Salvemini D., Johnson K.M. Blockade of phencyclidine-induced cortical apoptosis and deficits in prepulse inhibition by m40403, a superoxide dismutase mimetic. Journal of Pharmacology and Experimental Therapeutics 2003, 304:266-271.
59. Whittaker V.P., Barker L.A. The subcellular fractionation of brain tissue with special reference to the preparation of synaptosomes and their component organelles. Methods of Neurochemistry 1972, 2:1-52.
60. Willis C.L., Ray D.E. Antioxidants attenuate MK-801-induced cortical neurotoxicity in the rat. NeuroToxicology 2007, 28:161-167.
61. Winter J. Antagonism of phencyclidine-induced stimulus control in the rat by other psychoactive drugs. Pharmacology Biochemistry and Behavior 2008, 88:189-195.
62. Winter J., Eckler J., Rice K., Rabin R. Serotonergic/glutamatergic interactions: potentiation of phencyclidine-induced stimulus control by citalopram. Pharmacology Biochemistry and Behavior 2005, 81:694-700.
63. Yamada K., Kanba S., Anamizu S., Ohnishi K., Ashikari I., Yagi G., Asai M. Low superoxide dismutase activity in schizophrenic patients with tardive dyskinesia. Psychological Medicine 1997, 27:1223-1225.
64. Yao J.K., Leonard S., Reddy R. Altered glutathione redox state in schizophrenia. Disease Markers 2006, 22:83-93.
65. Yao J.K., Reddy R.D., van Kammen D.P. Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs 2001, 15:287-310.
66. Zuo D.-Y., Wu Y.-L., Yao W.-X., Cao Y., Wu C.-F., Tanaka M. Effect of MK-801 and ketamine on hydroxyl radical generation in the posterior cingulate and retrosplenial cortex of free-moving mice, as determined by in vivo microdialysis. Pharmacology Biochemistry and Behavior 2007, 86:1-7.